Microstructural Abnormalities in Subcortical Reward Circuitry of Subjects with Major Depressive Disorder by Blood, Anne J. et al.
Microstructural Abnormalities in Subcortical Reward
Circuitry of Subjects with Major Depressive Disorder
Anne J. Blood
1,3,5, Dan V. Iosifescu
1,6, Nikos Makris
1,4, Roy H. Perlis
1,2, David N. Kennedy
4,5, Darin D.
Dougherty
1, Byoung Woo Kim
1,3, Myung Joo Lee
1,3, Shirley Wu
1, Sang Lee
1,3, Jesse Calhoun
1,3, Steven M.
Hodge
1,3,4, Maurizio Fava
1,2, Bruce R. Rosen
3, Jordan W. Smoller
1,2, Gregory P. Gasic
1,3, Hans C.
Breiter
1,3* for the Phenotype Genotype Project on Addiction and Mood Disorders
1Depression Clinic and Research Program, Mood and Motor Control Laboratory, Addiction Research Program, Laboratory of Neuroimaging and Genetics, Department of
Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, 2Psychiatric and Neurodevelopmental Genetics
Unit and Center for Human Genetic Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, 3Motivation
and Emotion Neuroscience Collaboration (MENC) and Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital
and Harvard Medical School, Boston, Massachusetts, United States of America, 4Center for Morphometric Analysis and Center for Integrative Informatics, Massachusetts
General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, 5Department of Neurology, Massachusetts General Hospital and Harvard
Medical School, Boston, Massachusetts, United States of America, 6Mount Sinai School of Medicine, New York, New York, United States of America
Abstract
Background: Previous studies of major depressive disorder (MDD) have focused on abnormalities in the prefrontal cortex
and medial temporal regions. There has been little investigation in MDD of midbrain and subcortical regions central to
reward/aversion function, such as the ventral tegmental area/substantia nigra (VTA/SN), and medial forebrain bundle (MFB).
Methodology/Principal Findings: We investigated the microstructural integrity of this circuitry using diffusion tensor imaging
(DTI)in22MDDsubjectsandcomparedthemwith22matchedhealthycontrolsubjects.Fractional anisotropy(FA)valueswere
increased in the right VT and reduced in dorsolateral prefrontal white matter in MDD subjects. Follow-up analysis suggested
two distinct subgroups of MDD patients, which exhibited non-overlapping abnormalities in reward/aversion circuitry. The
MDD subgroup with abnormal FA values in VT exhibited significantly greater trait anxiety than the subgroup with normal FA
values in VT, but the subgroups did not differ in levels of anhedonia, sadness, or overall depression severity.
Conclusions/Significance: These findings suggest that MDD may be associated with abnormal microstructure in brain
reward/aversion regions, and that there may be at least two subtypes of microstructural abnormalities which each impact
core symptoms of depression.
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Introduction
It has been proposed that major depressive disorder (MDD) may
result from dysfunction of brain reward/aversion circuit-
ry[1,2,3,4,5,6,7]. Hypothesized in 1999 as a general schema for
processing both positive and negative features of potential ‘‘goal-
objects’’ or states [8], a generalized reward/aversion system that
processes the salience of stimuli across a continuum of aversion and
reward was described in multiple publications between 1996 and
2001 [9,10,11,12,13]. This work identified an extended set of brain
regions as variably processing a continuum between positive and
negative valence and intensity information, along with category and
incidence information from goal-objects. These observations have
been extensively replicated [14,15,16,17,18] and synopsized
[19,20,21]. The recent report of a law-like relationship between
patterns of approach and avoidance behavior to rewarding and
aversive stimuli further argues that the systems processing this
information do not function independently of one another [22].
The possibility that abnormalities in this reward/aversion
circuitry underlie many psychiatric conditions, including MDD,
was further schematized by multiple investigators [1,6,23,24].
Animal models of MDD strongly support this thesis and have
hypothesized dopaminergic midbrain nuclei and the medial
forebrain bundle (MFB) to be involved with the illness [7,25];
these subcortical regions are at the core of the animal literature
that first identified reward circuitry [26,27,28,29,30]. In humans
with MDD, there has recently been detection of functional
abnormalities in these subcortical regions [2,31,32], in addition to
well-established abnormalities in target regions receiving subcor-
tical projections [33,34,35,36,37,38,39,40,41,42,43,44,45,46,47].
However, there has not yet been an evaluation of microstructural
integrity in the midbrain nuclei or MFB.
The current study aimed to evaluate microstructural integrity of
subcortical brain reward/aversion circuitry in cohorts of subjects
with and without MDD, using approaches that maximized detection
sensitivity in subcortical regions. Our primary hypotheses focused on
evaluating brain microstructure in the midbrain ventral tegmental
area/substantia nigra (VTA/SN), the medial forebrain bundle
(MFB), and the amygdalofugal pathway (AFP). Our secondary a
priori hypotheses were based on a general evaluation of the broad set
of reward/aversion circuitry implicated in MDD [8,48].
We designed the study to take into consideration potential
heterogeneity within the MDD cohort [33,37,49,50,51,52,53,
54,55,56,57], given that this is a potential confound in group
designs [58]. Such an approach may not only improve methods,
but may also lead to identification of subgroups of MDD. We
hypothesized there would be microstructural heterogeneity in our
cohort that could not be predicted a priori by functional imaging
abnormalities or symptom profiles since MDD has been
hypothesized to be a systems-level disorder, and it is possible that
microstructural abnormalities at different points in a distributed
circuit could all lead to similar abnormalities in behavior/mood.
To address this, we allowed the DTI data itself to drive potential
segregation across patients.
Methods
Subjects
All subjects signed written informed consent prior to participa-
tion in this study, and the study was approved by the Institutional
Review Board of Massachusetts General Hospital (Partners
Human Research Committee). All experiments were conducted
in accordance with the principles of the Declaration of Helsinki.
22 of 44 subjects met DSM-IV criteria for Major Depressive
Disorder (MDD) diagnosed by physician-administered Structured
Clinical Interview for DSM-IV Axis I Disorders - Patient Edition
[SCID-P [59]] and were between the ages of 18 and 65 (mean
age=36.3612.1 years; 12/22 females, mean educational history
of 15.662.6 years, 19 Caucasian and 3 African American, 20/22
right-handed). These patients were matched one-to-one with 22
healthy volunteers on the following criteria: age (within 5 years),
years of education (within 5 years), gender, self-reported race, and
handedness (control mean age=35.3611.6 years; mean educa-
tional history of 15.762.1 years; 12/22 females, 19 Caucasian and
3 African American, 20/22 right-handed. Age and years of
education did not differ significantly across groups (age: F=0.001,
p=0.979;.education: F=0.085, p=0.772). This tight matching
was done because each of these factors may potentially influence
neural structure and function. All subjects were drawn from a
larger study evaluating cocaine addicted, depressed and control
subjects [The Massachusetts General Hospital (MGH) Phenotype
Genotype Project in Addiction and Depression (PGP; http://pgp.
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larger cohort of individuals with MDD (n=47) because they met
quality assurance criteria, including (a) minimal residual motion
artifacts after motion correction of DTI images, (b) absence of MR
susceptibility artifacts, and (c) availability of control subjects which
met the strict matching criteria described above, and who also had
DTI data without motion or susceptibility artifacts.
MDD subjects were excluded if they met DSM-IV criteria for
primary psychotic disorders, bipolar disorder, eating disorders,
substance abuse disorders, generalized anxiety disorder, panic
disorder, PTSD or OCD by SCID interview (current or lifetime);
healthy volunteers were excluded if they met DSM-IV criteria for
any Axis I psychiatric disorder by SCID interview.
Additional exclusion criteria for both MDD subjects and healthy
volunteers were: 1) currently suicidal or at risk for suicide in the
judgment of the investigator; 2) pregnant women; 3) carrying a
medical device incompatible with MRI (e.g., metal implants such as
surgical clips or pacemakers) or significant claustrophobia or weight
that would make MRI unfeasible; 4) serious medical illness including
a knownhistoryofHIV-1+ status;5) Subjects with insulin dependent
diabetes mellitus (IDDM) or subjects with noninsulin dependent
diabetes mellitus (NIDDM) and abnormal Hemoglobin A1C; 6)
severe respiratory compromise; 7) history of head trauma with
neurological sequelae, including multiple concussions and/or history
ofstroke;8)historyofseizure disorder,delirium,dementia,ormental
disorders due to general medical conditions; 9) clinical or laboratory
evidence of uncontrolled hypothyroidism or hyperthyroidism; and
10) subjects which, in the opinion of the Management Group
running the PGP, were not able to participate safely in this study. In
addition, subjects in the larger PGP study were screened for
Hepatitis C (by Hepatitis C+ titer); no subjects included in this study
tested positive for Hepatitis C. Three MDD subjects and one control
subject had a history of tobacco use (one current smoker in MDD
cohort, one current smoker in the control cohort, and two previous
smokers in the MDD cohort).
In addition to screening for exclusion criteria, we also
performed for all subjects (MDD and healthy controls): (1) the
Structured Clinical Interview for DSM-IV for Axis I disorders
(SCID-I); (2) a medical history and concurrent medication status
(see Table 1 for medication status in relation to MDD subgrouping
and VTA/SN FA values); (3) sociodemographic information; (4)
Edinburgh Handedness assay; (5) blood and urinary analysis; (6)
Inventory of Depressive Symptomatology – Self Report (IDS-SR);
(7) 31-item Hamilton Rating Scale-Depression (HAM-D, [60]);
and (8) the STAI (Spielberger State Trait Anxiety Inventory).
DTI Scanning Protocol
During each scanning session, a high-resolution (2 mm
isotropic) whole head DTI scan was acquired on a Siemens 3.0
Tesla Sonata Magnet System (Siemens AG, Medical Solutions,
Erlangen, Germany); TR=24 s; TE=81 ms; slice thick-
ness=2 mm, 60 slices total, 1286128 matrix, 2566256 mm
FOV, 6 averages, 6 noncolinear directions with b value=700 s/
mm
2, and 1 image with b-value=0 s/mm
2. DTI scans were
acquired using auto-align software [61] to normalize brain image
slice orientation across subjects. Slices were situated parallel to the
AC-PC line, and parallel to the inside curve of the FOC to
minimize signal distortion in this region [62].
DTI Image Preprocessing and Registration
1. DTI preprocessing. All data processing was performed
using Freesurfer software (http://surfer.nmr.mgh.harvard.edu) and
FSL (http://www.fmrib.ox.ac.uk/fsl) processing streams. Detailed
methods for preprocessing DTI data aredescribed in Salat et al.[63].
Briefly, each tensor volume from the DTI dataset was resampled to
the T2 image to correct for remaining eddy current distortion, and to
correct for head motion. The fractional anisotropy (FA) metric was
derived from the diffusion tensor as previously described [64]. All
resulting maps were resampled to 1 mm
3 resolution. Images were
inspected for residual motion and susceptibility artifacts; subjects with
significant artifacts were excluded.
2. Image registration. FA maps were registered to a
Montreal Neurological Institute (MNI) ICBM152 T2 template
for the voxel-based contrast and subsequent analyses; all contrast
analysis results are reported in MNI coordinates. Registration
procedures (both automated and manual) were done blinded to
subject and group identification. Given the small size of our areas
of interest, our methods included registration techniques designed
to maximize intersubject alignment in our areas of interest.
Registration and analysis of the VTA/SN, in particular, has been
previously shown to be valid and informative, given abnormalities
have been detected in the SN in patients with Parkinson’s Disease,
a population known to exhibit structural pathology in this region
[65,66]. In PD patients, FA was decreased in the SN, which is
consistent with neuronal loss in this region [65,66]. While the
Parkinson’s studies did not use our directed registration methods,
Table 1. Antidepressant History and Status for MDD Cohort.
FA value in VTA/
SN cluster
History of treatment
with antidepressants?
On antidepressant(s) at
time of scanning?
Normal VTA/SN
subgroup
0.263588 No No
0.332777 Yes Yes
0.353066 Yes Yes
0.362028 Yes No
0.390219 No No
0.39181 Yes No
0.410209 Yes Yes
0.417723 No No
0.434277 No No
0.43575 No No
0.448794 Yes Yes
0.455736 Yes No
Abnormal VTA/SN
subgroup
0.544226 Yes No
0.546144 No No
0.54869 Yes No
0.602679 Yes Yes
0.603839 No No
0.612006 Yes No
0.646446 Yes Yes
0.658727 Yes Yes
0.67705 No No
0.745329 Yes No
Antidepressant history and current status were determined during study
screening based on the SCID evaluation (history) and a questionnaire reporting
current medication status. A yes response indicates a positive history and/or
current usage with an identified antidepressant medication and dosage.
doi:10.1371/journal.pone.0013945.t001
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to be much greater in Parkinson’s patients, making it less
susceptible to being masked by imprecision in registration of
small nuclei by automated methods (i.e. ‘‘noise’’). Thus, in a
disorder where we expect more subtle abnormalities in this region
(e.g., MDD), we believe the directed registration methods were
required to resolve the signal above the noise.
a. Automated registration. The initial image registration was done
using FSL software to perform an automated, 12-degrees of
freedom, global affine transformation[67]. The linear affine
transformation (in combination with a subsequent landmark-
guided manual registration) was selected over non-linear transform
methods to minimize loss of signal due to warping, which is
relatively greater in the small subcortical regions [68] relevant to
our a priori hypotheses.
b. Manual registration. After the automated registration, all
registered images were put through an additional manual
registration step using Martinos Center Freesurfer software
(http://surfer.nmr.mgh.harvard.edu). This step maximized the
accuracy of registration of each subject’s FA map to ICBM152 T2
space, based on three registration landmarks selected to maximize
registration in our a priori areas of evaluation (AOEs) (see Text S1).
Figures S1, S2, S3, S4 illustrate anatomical co-localization across
MDD and control cohorts overall, and within our primary AOEs.
Data Analysis
1. A priori hypotheses and segmentation of a priori areas
of evaluation (AOEs). Primary and secondary a priori
hypotheses corresponded to a priori AOEs for constraining our
voxel-based search of patient/control differences. These AOEs
constrained which voxels were evaluated in FA map group
contrasts, to identify clusters meeting volume and significance
thresholds. AOEs were segmented by an anatomist (N.M.) using
landmark-based, atlas-guided definitions of the regions (see Text
S1 and Figures S1, S2, S3, S4, S5, S6, S7).
a. Primary a priori hypothesis. We predicted MDD subjects would
exhibit abnormal brain microstructure in (1) the medial forebrain
bundle (MFB) and contiguous lateral nucleus of the hypothalamus
(LNH), along with (2) regions feeding the MFB/LNH, including
the ventral tegmental area/substantia nigra (VTA/SN), and (3) the
amygdalofugal pathway. Follow-up analyses (described below),
considered clusters falling within these regions.
b. Secondary a priori hypotheses. Based on imaging findings in the
MDD literature, we further hypothesized that MDD subjects
would exhibit abnormal brain microstructure in white matter
adjacent to orbitofrontal cortex (FOC), anterior cingulate cortex
(ACC), paracingulate cortex (PAC), subgenual prefrontal cortex
(SGC), and dorsolateral prefrontal cortex (DLPFC).
c. Brain regions outside a priori hypothesized AOEs. We evaluated all
other brain regions outside primary and secondary a priori AOEs
using a whole-brain Bonferroni correction.
2. Voxel-based contrast of FA maps for MDD subjects
versus control subjects. a. Contrast analysis. A voxel-based
contrast analysis was performed between MDD and control
subjects, using a two-tailed t-test with Freediffusion software
[63,69]. To minimize the chance of false positives we required (1)
that group differences meet a cluster threshold and (2) that the p
value of the peak voxel within each cluster meet a correction for
the number of voxels in a search volume.
b. Cluster thresholds for group contrast of FA maps. For primary ap r i o r i
AOEs, the cluster threshold was at least 9 contiguous voxels, with
p,0.05 for each voxel. This was increased to 27 contiguous voxels
for secondary ap r i o r iAOEs, and 81 contiguous voxels for regions
outside ap r i o r iAOEs. The least stringent threshold exceeded cluster
thresholds used with fMRI [30,70] and cortical thickness analy-
sis[71]. We defined contiguous voxels as voxels sharing an edge
(i.e., not just a corner). To be considered within that AOE, greater
than 50% of voxels in a cluster had to fall within a segmented ap r i o r i
AOE.
c. Multiple comparisons correction for group contrast of FA maps.T ob e
considered statistically significant, clusters were required to have a
peak voxel meeting a Bonferroni correction for multiple
comparisons. Corrections were based on the total number of
voxels in the area being considered (418 for primary a priori AOEs;
9,308 for secondary a priori AOEs; 200,000 for the whole brain
[i.e., not a priori]), divided by the required cluster size. Thus, the
uncorrected p value (reported in Tables 2, 3, 4) was required to be
p,0.05/(418/9), or p,0.00108, for primary a priori AOEs,
p,0.05/(9,308/27), or p,1.45610
24, for secondary a priori
AOEs, and p,0.05/(200,000/81), or 2.03610
25, for the rest of
the brain. Peak voxels within an order of magnitude of the
corrected p value were considered trends toward significance. All
regions that met cluster threshold criteria were tabulated; however,
the results and discussion sections focus primarily on regions which
met full significance criteria.
d. Permutation test as validation of our findings. As a supplemental test
to further validate the robustness of findings, we computed a
permutation test for regions meeting the cluster threshold.
Methods and results for this analysis are reported in Tables S1,
S2, S3, S4, S5, S6 in Dataset S1.
e. Laterality test. Given initial findings in the VTA/SN region
were lateralized to the right hemisphere in MDD subjects, we
assessed laterality of FA in this region for both groups to
distinguish between potential presence of lateralized effects in
patients, versus potential loss of laterality relative to controls (see
Dataset S2).
3. Follow-up analyses. Follow-up analyses were conducted
to assess MDD group heterogeneity, and the relationship between
FA and symptom profiles for MDD subjects.
a. Individual subject FA values. Once clusters representing group
differences were identified in primary a priori AOEs, we measured
mean FA across each cluster for each subject (see Figures S5, S6
for illustrations of these clusters). Mean FA values for individuals
were then used in follow-up analyses. To evaluate whether MDD
cohort heterogeneity led to false negatives, we included findings
which met the cluster, but not the Bonferroni threshold in the
initial voxel-based contrast.
b. Gapping analysis for individual FA values in MDD subjects. We used
a gapping analysis [72] to test the likelihood that there were gaps
in the distribution of FA values in the MDD cohort, suggesting the
presence of two or more population distributions of these values.
This analysis involved rank ordering individual VTA/SN FA
values and calculating the mean gap distance between each of the
middle 50% of values (eliminating the top 25% and bottom 25%
of values to exclude potential outliers). The ratio of each individual
gap distance between adjacent data points was calculated relative
to mean gap distance. Finally, we identified the greatest gap ratio
within the middle 50% of values and calculated the likelihood that
this gap ratio would be observed by chance if data points reflected
the distribution of a single population. This likelihood was
calculated both for a Gaussian distribution and for a t distribution
with df=4. Each statistic was calculated using 10,000 simulations.
c. Voxel-based contrasts of FA maps for the two MDD subgroups.A
voxel-based contrast was calculated for each of the two subgroups
of MDD subjects identified in the gapping analysis versus their
individually matched controls. Clusters were identified in these
voxel-based contrasts and peak voxels corrected for multiple
comparisons using the same criteria as in the initial group contrast.
DTI-Based Subgroups in MDD
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symptom profiles differed across the two MDD subgroups.
Specifically, we looked at (1) overall depression severity (total score
on IDS-SR), and scores on individual IDS-SR items relating to (2)
anhedonia (question 21), (3) sadness (question 5), and (4) psychomo-
tor symptoms (question 30). Although MDD subjects in our cohort
had not been clinically subtyped, anxious depression is one of the
most common clinical subtypes of MDD [57,73]; therefore we also
evaluated measures of (5) trait anxiety (via the STAI-T). We used
two-tailed t-tests to evaluate whether these measures differed
between MDD subgroups. Significance was determined using a
Bonferroni correction of p,0.05/5=0.01 for these analyses.
Table 3. Post-Hoc Contrast for ‘‘Abnormal VTA/SN’’ MDD Subgroup (10 MDD Versus 10 Matched Controls).
Region
MNI coordinates at peak
difference t (p) values at peak difference Cluster size (# voxels)
FA group differences which met the 9-voxel cluster requirement in the primary a priori areas of evaluation (AOEs)
R. VTA/SN 11.4 221.1 211.9 6.62 (0.0000032)* 49
L. VTA/SN 25.7 219.2 217.2 3.90 (0.00106)* 13
FA group differences which met the 27-voxel cluster requirement in the secondary a priori AOEs
L. DLPFC wm (superior fr. gyrus) 215 26.9 32.8 23.31 (0.00394) 50
L. DLPFC wm (middle fr. gyrus) 237.7 27.5 27.7 23.82 (0.00127) 33
FA group differences which met the 81-voxel cluster requirement in other regions
R. FOC (olf sulcus) gm 9.5 17.9 215.4 4.96 (0.000102) 95
R. SGC gm 7.6 10.7 25.8 4.63 (0.000210) 118
R. PMC wm (SLF3) 53 9.2 15.2 25.95 (0.000012)* 106
MDM/PAG region 0 224.6 27.2 4.26 (0.000471) 78 (just below
significance)
Positive t values indicate FA values were elevated in MDD subjects relative to control subjects; negative t values indicate FA values were reduced in MDD subjects
relative to control subjects. p values are reported uncorrected; symbols indicate significance and trends at the corrected threshold.
*p value met the corrected threshold.
{p value was within an order of magnitude of the corrected threshold (a trend).
Abbreviations: R: right hemisphere; L: left hemisphere; wm: white matter; gm: gray matter; VTA/SN: ventral tegmental area/substantia nigra; DLPFC: dorsolateral
prefrontal cortex; FOC: orbitofrontal cortex; SGC: subgenual cortex; PMC: premotor cortex; CCtx: calcarine cortex; MDM/PAG: medial dorsal midbrain/periaqueductal gray.
doi:10.1371/journal.pone.0013945.t003
Table 2. Voxel-Based Contrast for the Whole Cohort (22 MDD Versus 22 Matched Controls).
Region
MNI coordinates at peak
difference t (p) values at peak difference
Cluster size
(# voxels)
FA group differences which met the 9-voxel cluster requirement in the primary a priori areas of evaluation (AOEs)
R. VTA/SN 11.5 219.2 213.6 3.56 (0.000929)* 17
L. MFB/LNH 29.5 23.9 211.8 23.20 (0.00264){ 9
FA group differences which met the 27-voxel cluster requirement in the secondary a priori AOEs
R. ACC wm 19.2 32.7 24.7 23.79 (0.000472){ 35
R. DLPFC wm (superior fr. gyrus) 18.3 26.5 49.5 24.00 (0.000252){ 27
L. DLPFC wm (superior fr. gyrus) 213.3 23.1 44.1 24.01 (0.000245){ 55
L. DLPFC wm (middle fr. gyrus) 238.6 26.0 31.5 23.20 (0.00262) 40
L ACC/PAC wm 29.5 38.5 17.0 23.49 (0.00113) 33
FA group differences which met the 81-voxel cluster requirement in other regions
L. PMC wm (SLF3) 243.9 0.0 18.9 24.50 (0.000052){ 81
R. PMC wm (SLF3) 45.5 0.0 17.0 24.15 (0.000160) 134
L./midline CC 24.7 5.3 22.5 23.56 (0.000937) 98
R. CCtx wm 30.6 257.5 2.6 5.54(0.0000018)* 83
L. CCtx wm 221.0 260.1 2.7 4.29 (0.000102) 99
Positive t values indicate FA values were elevated in MDD subjects relative to control subjects; negative t values indicate FA values were reduced in MDD subjects
relative to control subjects. p values are reported uncorrected; symbols indicate significance and trends at the corrected threshold.
*p value met the corrected threshold.
{p value was within an order of magnitude of the corrected threshold (a trend).
Abbreviations: R: right hemisphere; L: left hemisphere; wm: white matter; gm: gray matter; VTA/SN: ventral tegmental area/substantia nigra; MFB: medial forebrain
bundle; LNH: lateral nucleus of the hypothalamus; ACC anterior cingulate cortex; DLPFC: dorsolateral prefrontal cortex; PAC: paracingulate cortex; PMC: premotor cortex;
CC: corpus callosum; CCtx: calcarine cortex.
doi:10.1371/journal.pone.0013945.t002
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1. Image Contrast Analysis of MDD Versus Control
Subjects
a. Primary a priori areas of evaluation (AOEs) (Table 2;
Figure 1). Significantly elevated FA was detected in MDD
subjects within the VTA/SN. Specifically, FA was elevated at the
ventral/lateral edge of the right SN adjacent to the cerebral
peduncle and overlying the nigral fiber system (striatonigral,
nigrostriatal, and corticostriatal fibers; Figure 1). A trend toward
reduced FA in MDD subjects was also noted in the left MFB where
it passes through the LNH. There were no group differences for the
amygdalofugal AOE. Mean FA values for each cluster detected in
the voxel-based contrast are reported in Table S2.
b. Secondary a priori AOEs (Table 2; Figure 2). There
were trends toward significantly reduced FA in two white matter
regions underlying DLPFC (Figure 2), and in white matter
adjacent to the right ACC.
c. Other regions meeting the cluster threshold (Table 2;
Figure 3). Outside a priori AOEs, MDD subjects exhibited
significantly elevated FA in white matter adjacent to right
calcarine cortex (Figure 3B), and a trend toward significantly
reduced FA in white matter within the left precentral gyrus, below
premotor cortex (BA6) (Figure 3A).
2. Follow-up Analyses: Gapping, Subgroup Subtractions,
Symptom Correlations
a. Gapping analysis. A gap in the distribution of mean FA
values across MDD subjects was observed for the VTA/SN cluster
(Figure 4A). This gap was located at the upper limit of control
values; all MDD subjects with values above the gap were outside
the range of control values. Gapping analysis indicated it was
unlikely that this gap in the MDD VTA/SN FA values would have
been observed by chance if this were a homogeneous population
(p=0.001 with a Gaussian distribution; p=0.005 for a t
distribution, df=4). Ten MDD subjects fell above the gap
(‘‘abnormal VTA/SN’’ subgroup), and 12 fell below it (‘‘normal
VTA/SN’’ subgroup). There were no statistically significant gaps
across MDD subjects for the MFB/LNH cluster.
b. Voxel-based contrasts of FA maps for the two MDD
subgroups. MDD subgroups exhibited two non-overlapping
sets of brain microstructural abnormalities when contrasts were
conducted separately (Figures 4, 5, 6).
(1) Abnormal VTA/SN MDD subgroup versus matched control subjects
(Table 3, Figures 4, 5). For MDD subjects with FA values above the
gap, a VTA/SN cluster in the right hemisphere covered a
significant proportion of the SN and its peak was centered within
the SN (Figure 4B). Voxels in this cluster extended into the lateral
VTA. There was also a cluster of significantly elevated FA in the
left hemisphere VTA/SN (Figure 4B). This subgroup exhibited
significantly reduced FA in white matter underlying right
premotor cortex (Figure 5). Mean FA values for clusters are
reported in Table S4. This subgroup did not exhibit FA
abnormalities within the MFB/LNH a priori AOE (Figure 4C),
or within ACC white matter.
(2) Normal VTA/SN MDD subgroup versus matched control subjects
(Table 4; Figures 4, 6). The MDD subgroup with VTA/SN FA
values below the gap, exhibited a trend toward reduced FA in the
left MFB/LNH (Figure 4C), and a trend toward reduced FA in
white matter adjacent to right ACC (Figure 6). Mean FA values
within clusters are reported in Table S6. This subgroup did not
exhibit FA abnormalities within the VTA/SN a priori AOE
(Figure 4B) or premotor white matter.
c. Symptom measures inabnormalversus normal VTA/SN
MDD subgroups. Total IDS-SR scores, and scores for items
relating to anhedonia, sadness, and psychomotor symptoms did not
differ between the normal and abnormal VTA/SN subgroups
(Table5). In contrast, traitanxietyscores (STAI-T)were significantly
different between abnormal and normal VTA/SN MDD subgroups
[t(2,19)=2.96, p=0.0084, normal VTA/SN mean=51.2768.96,
abnormal VTA/SN mean=61.8067.32; Figure 7].
Discussion
In this study, MDD subjects exhibited brain microstructural
differences in subcortical reward/aversion regions, specifically the
VTA/SN,compared to controlsubjects.IndividualFA valuesinthe
VTA/SN divided the MDD cohort into subgroups with distinct
profiles of microstructural abnormalities and different levels of trait
anxiety, but no difference in other clinical symptoms of MDD. This
subtyping supports a hypothesis that etiology and symptoms of
MDD may not match one-to-one, although distinguishing clinical
factors may be associated with a given etiology.
Evidence That MDD Is Characterized By Reward/Aversion
Circuitry Abnormalities
FA abnormalities in the VTA/SN region. In the initial
voxel-based contrast, FA was elevated in MDD subjects at the
border of the SN and cerebral peduncle in a region that, according
to anatomic atlases, contains nigrostriatal projection fibers.
Table 4. Post-Hoc Contrast for ‘‘Normal VTA/SN’’ MDD Subgroup (12 MDD Versus 12 Matched Controls).
Region
MNI coordinates at peak
difference t (p) values at peak difference Cluster size (# voxels)
FA group differences which met the 9-voxel cluster requirement in the primary a priori areas of evaluation (AOEs)
L. MFB/LNH 211.3 23.3 29.8 23.19 (0.00425){ 20
FA group differences which met the 27-voxel cluster requirement in the secondary a priori AOEs
R. ACC wm 15.2 31.6 23.2 23.83 (0.000913){ 31
L ACC/PAC wm 29.4 38 13.8 23.56 (0.00175) 46
Positive t values indicate FA values were elevated in MDD subjects relative to control subjects; negative t values indicate FA values were reduced in MDD subjects
relative to control subjects. p values are reported uncorrected; symbols indicate significance and trends at the corrected threshold.
*p value met the corrected threshold.
{p value was within an order of magnitude of the corrected threshold (a trend).
Abbreviations: R: right hemisphere; L: left hemisphere; wm: white matter; MFB: medial forebrain bundle; LNH: lateral nucleus of the hypothalamus; ACC anterior
cingulate cortex; PAC: paracingulate cortex.
doi:10.1371/journal.pone.0013945.t004
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not exhibit the abnormality in the VTA/SN, we viewed the voxel-
based contrast for the MDD subgroup with abnormal VTA/SN
FA as a better reflection of the location and extent of this
abnormality. This follow-up analysis revealed a patient/control
difference peak centered within the SN, which covered a
significant proportion of the SN and extended into the lateral
VTA in both hemispheres, suggesting the VTA/SN finding was
not a localized effect specific to the nigrostriatal fibers, and that the
effect was seen in the nucleus, rather than the adjacent white
matter.
Etiological considerations for increased FA in the VTA/
SN. The goal of the current study was to identify regions in
which brain microstructure was different in MDD, independent of
specific etiology, which can be associated with other known
structural abnormalities, clinical or behavioral features in a
population. Although DTI evaluates water diffusion properties
and therefore can be influenced by many potential etiologies, there
are certain etiologies commonly associated with abnormalities in
white matter, and emerging evidence for abnormalities underlying
FA changes in mixed gray/white matter regions; these can be
considered here in relation to generating new hypotheses to test in
MDD. Specifically, white matter FA is influenced by the integrity
of axons and myelin, as well as directional coherence of axons
[74], with reduced FA suggesting either a loss of axonal integrity or
coherence. Although the basis for altered FA in gray matter
regions has not been as well studied, a number of potential
alterations in cell or axonal composition within these regions may
alter water diffusion properties; this includes reduced cell density
and/or cell loss, altered cell structure, or altered integrity or
orientation of the cells or axons projecting out of the region.
Altered FA has been previously shown in brainstem nuclei in the
presence of known neuronal loss, including altered FA in the SN in
Parkinson’s Disease [e.g. [65,66]], confirming the potential for FA
to detect pathology-relevant changes in the VTA/SN region.
While neuronal loss, as occurs in Parkinson’s Disease, would be
expected to lead to reduced FA [65,66], a reduction in glial density
could potentially lead to elevated FA due to an increase in the ratio
of axons to cell bodies. Evidence for such an effect is seen in a
recent study in a mouse model of Pelizaeus-Merzbacher disease
(PMD), in which there is transient astrocytic hypertrophy in
females. Hypertrophy in these animals was associated with
reduced FA, while FA subsequently increased upon the reversal
of hypertrophy [75]; i.e. when glial density decreased, FA
increased. Elevated FA in a mixed gray/white matter region has
also been directly demonstrated in association with induction of a
disease process. A recent study showed that an animal model of
febrile seizures exhibited elevated FA in the hippocampus
following seizure induction [76]. In humans, such seizures
promote hyperexcitability of the limbic system and are accompa-
nied by structural and metabolic abnormalities of the limbic
system.
Given that reduced glial density has been demonstrated in
MDD in the SGC [77] along with imaging abnormalities in this
and other prefrontal gray matter regions in MDD, [34,78,79], we
suggest that future studies can test the hypothesis that there may
Figure 1. FA difference in MDD subjects in primary a priori
areas of evaluation. This figure shows the significant FA difference in
MDD subjects versus matched healthy controls for the voxel-based
contrast (all subjects: 22 MDD, 22 controls) within areas of evaluation
(AOEs) included in our primary a priori hypotheses. MDD subjects
exhibited elevated FA in the ventral tegmental area/substantia nigra
(VTA/SN), which localized to the ventral/lateral edge of the substantia
nigra (SN) adjacent to the cerebral peduncle, and the nigral fiber system
(striatonigral, nigrostriatal, and corticostriatal fibers). Translucent green
in image on left indicates the a priori AOE for the VTA/SN in the slice
shown, which was used to constrain the initial contrast analysis. The
color bar indicates the range of p values in this figure, from the
threshold (p,0.05) to the order of magnitude of the voxel of peak
significance (i.e. smallest p value) in the VTA/SN; color in images is
viewed using trilinear interpolation. Warm tones (red, orange, yellow)
indicate regions in which MDD subjects exhibited elevated FA relative
to control subjects. RH: right hemisphere; LH: left hemisphere.
doi:10.1371/journal.pone.0013945.g001
Figure 2. FA differences in MDD subjects in secondary a priori
areas of evaluation. This figure shows the significant FA differences
in MDD subjects versus matched healthy controls for the voxel-based
contrast (all subjects: 22 MDD, 22 controls) in a priori regions of
evaluation (AOEs) included in our secondary a priori hypotheses. MDD
subjects exhibited reduced FA in white matter regions underlying
dorsolateral prefrontal cortex (DLPFCwm), bilaterally. Translucent green
in images on left indicates the a priori AOE for DLPFCwm in the slices
shown, which were used to constrain the initial contrast analysis. The
color bar indicates the range of p values in this figure, from the
threshold (p,0.05) to the order of magnitude of the voxel of peak
significance (i.e. smallest p value) in DLPFCwm; color in images is
viewed using trilinear interpolation. Cool tones (blues) indicate regions
in which MDD subjects exhibited reduced FA relative to control
subjects. RH: right hemisphere; LH: left hemisphere.
doi:10.1371/journal.pone.0013945.g002
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the FA abnormality observed here. Since glia are thought to be
critical in synapse formation and synaptic plasticity [80,81],
reduced density and/or loss of glia would have a critical impact on
information processing in the reward/aversion circuitry. An
alternate possibility is that cell morphology is altered in MDD
subjects. Russo and colleagues have shown that chronic drug use
leads to a reduction in neuronal size in the VTA in an animal
model of chronic opiate addiction [82]. This size reduction was
accompanied by a reduction in the rewarding effects of morphine.
In MDD, analogous factors, such as chronic stress, might have a
similar effect on neurons in this region.
Functional implications of the VTA/SN abnormality for
MDD and reward/aversion processing. Within the VTA/
SN region, the VTA predominantly processes reward/aversion
information [18,27], while the SN processes both reward/aversion
and motor information [83]. The SN is thought to participate in
modulating reward prediction and expectancy [84], as well as
prediction of aversive and negatively valenced stimuli [18]. In
addition, medial portions of the SN project to and receive
projections back from the ventral striatum [30,70], which
processes reward/aversion information [21], while more lateral
portions project to the dorsal striatum, which processes motor
information [83]. These regions appear to be interconnected in an
ascending spiral so that information relating to reward/aversion
and motor function is likely mixed in this circuitry [83]. Other
efferents of the SN include GABAergic nigro-collicular pathways
which have been shown to mediate fear/defense reactions [85].
Taken together, the literature above suggests a hypothesis that
altered systems for reward/aversion prediction might lead to an
alteration in the capacity of some MDD subjects to assess realistic
likelihoods of aversive events [86]. Such individuals, as a
consequence, would be likely to show impaired expectancies
around negative events and compensate by maintaining higher
levels of vigilance/arousal for bad outcomes, which would be
clinically observed in the form of higher anxiety [87,88]. The
observation of significantly higher levels of trait anxiety in the
abnormal VTA/SN MDD subgroups supports such a hypothesis.
Given that the SN and VTA each project to the ventral striatum
[89], our findings are also consistent with reports of altered nucleus
accumbens function in MDD [2,32], supporting earlier hypotheses
of such an effect [1].
FA abnormalities in premotor cortex. Independent of a
priori regions, MDD subjects exhibited a trend toward reduced FA
in white matter underlying premotor cortex in the cohort as a
whole, which was significant in the abnormal VTA/SN group.
Since a number of tracts run through this region, we cannot be
certain that this finding reflects an abnormality in motor fibers.
Nevertheless, this finding is of interest in conjunction with the FA
abnormality in the SN, given these regions are each key
components of motor circuitry, and some MDD subjects in our
cohort exhibited psychomotor symptoms.
Evidence For Subtyping of the MDD Cohort Based on DTI
Measures and Relationship to Depressive Symptoms
There are three findings arguing that subjects with normal
versus abnormal VTA/SN FA fell into two biologically relevant
subtypes. The first is the observed gap in the middle of the
distribution of FA values for MDD subjects, which coincided with
the cut-off for control values. The second is that there was no
overlap in regional localization of FA abnormalities for the two
subgroups when evaluated separately. The third is the difference
in trait anxiety between groups, with higher mean trait anxiety in
the abnormal VTA/SN subgroup. The evidence here for MDD
subtyping based on features of the VTA/SN resonates with a
recent finding of differences in midbrain resting metabolism
between groups of patients whose depressive symptoms did versus
did not remit in response to antidepressants [31]. Although Milak
and colleagues [31] did not test whether there was a division on an
Figure 3. FA differences in MDD subjects in regions not in our a priori areas of evaluation. This figure shows the significant FA differences
in MDD subjects versus matched healthy controls for the voxel-based contrast (all subjects: 22 MDD, 22 controls) in regions not included in our a
priori hypotheses. MDD subjects exhibited (A) reduced FA in white matter adjacent to right premotor cortex (PMCwm), and (B) elevated FA in white
matter adjacent to right calcarine cortex (CCtx). The color bar indicates the range of p values in this figure, from the threshold (p,0.05) to the order
of magnitude of the voxel of peak significance (i.e. smallest p value) in PMCwm for reduced FA and from the threshold (p,0.05) to the order of
magnitude of the voxel of peak significance in CCtx white matter for elevated FA, color in images is viewed using trilinear interpolation. Warm tones
(red, orange, yellow) indicate regions in which MDD subjects exhibited elevated FA relative to control subjects; cool tones (blues) indicate regionsi n
which MDD subjects exhibited reduced FA relative to control subjects. RH: right hemisphere; LH: left hemisphere.
doi:10.1371/journal.pone.0013945.g003
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mictrostructural subgroups in the current study may also predict
treatment responsiveness and could be tested as a potential
diagnostic/prognostic biomarker. Future studies will be necessary
to evaluate the relationship between altered microstructure and
treatment responsiveness.
In contrast, no significant differences in two core symptoms of
depression (anhedonia and sadness) or overall depression severity
were observed between the two MDD subgroups. While this could
potentially reflect a power issue, it is also possible that the neural
subgroups observed here are an example of how the same illness
can arise when related components of the reward/aversion
circuitry are ‘‘hit’’ in different places. These data support the idea
that it may be the functional system (i.e. reward/aversion) hit, and
not the specific etiology of that hit, that determines whether an
individual develops MDD [1,48,90]. There is, however, potential
for vast differences in a subset of clinical symptoms, such as
anxiety, and in treatment responsiveness across different biological
etiologies.
The higher trait anxiety levels in the abnormal VTA/SN
subgroup are consistent with research connecting the VTA/SN to
expectancy processing [84], and connects with the idea that
abnormal anxiety may reflect altered expectancy [86,88]. Elevated
trait anxiety in this subgroup is also consistent with findings by
Figure 4. Subgrouping of MDD cohort based on individual FA values. This figure shows the subgrouping of the MDD cohort based on
individual FA values, and double dissociation of VTA/SN and MFB abnormalities across these two subgroups. (A) Scatterplots of FA values from the
VTA/SN cluster from MDD subjects (blue) and control subjects (pink). There was a statistically significant gap in the middle of the VTA/SN values for
MDD subjects; the values above this gap were all outside the range of control values. When contrasts were calculated separately for MDD subjects in
the abnormal VTA/SN (10 MDD and 10 controls) versus the normal VTA/SN (12 MDD and 12 controls) MDD subgroups, (B) abnormal VTA/SN MDD
subjects exhibited significantly elevated FA bilaterally in the ventral tegmental area/substantia nigra (VTA/SN), localized to both the SN and the VTA
and a trend toward significance in this region in the left hemisphere, while (C) MDD subjects in the normal VTA/SN subgroup did not exhibit any
significant FA differences in this region. In contrast, (B) abnormal VTA/SN MDD subjects did not exhibit any significant FA differences overlying the
medial forebrain bundle/lateral nucleus of the hypothalamus (MFB/LNH), while (C) normal VTA/SN MDD subjects exhibited a trend toward significant
reduction in FA values in this region. Translucent green in images on left indicates a priori AOEs for the (B) VTA/SN and (C) MFB/LNH in the slices
shown, which were used to constrain the initial contrast analysis. The color bar indicates the range of p values in this figure, from the threshold
(p,0.05) to the order of magnitude of the voxel of peak significance (i.e. smallest p value) in the VTA/SN for elevated FA and from the threshold
(p,0.05) to the order of magnitude of the voxel of peak significance in the MFB for reduced FA, color in images is viewed using trilinear interpolation.
Warm tones (red, orange, yellow) indicate regions in which MDD subjects exhibited elevated FA relative to control subjects; cool tones (blues)
indicate regions in which MDD subjects exhibited reduced FA relative to control subjects. RH: right hemisphere; LH: left hemisphere.
doi:10.1371/journal.pone.0013945.g004
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model of MDD induced by chronic stress. Clinically, our findings
in the VTA/SN support hypotheses regarding involvement of the
midbrain dopamine reward circuitry in MDD [7], and support
investigation of interventions based thereon [91].
Limitations of the Interpretation of Our Findings
Several factors inherent to patient imaging studies must be
considered for interpretation of findings such as ours. These
include the cohort size in relation to subgrouping, the balance
between strengths and weaknesses of our selection of registration
methods, the issue of whether microstructural abnormalities are
primary or secondary to MDD, and medication status of patients.
These factors are discussed below.
Cohort size, subgrouping, and thresholding. Our search
for heterogeneity within the MDD cohort was primarily for the
purpose of showing potential reasons previous DTI studies may
have exhibited false negatives in subcortical regions. The potential
clinical relevance of the subgroups identified is of great interest;
however, we emphasize that these findings are preliminary and
need to be replicated in larger cohorts. It is also possible that either
the cohort size of the subgroups or our conservative thresholds led
to false negatives in the current study, particularly in regions that
reached the level of a trend (e.g. the MFB). The current study
Figure 5. FA difference in the abnormal VTA/SN MDD
subgroup in premotor cortex. This figure shows the significant FA
difference in MDD subjects versus matched healthy controls for the
voxel-based contrast in the abnormal VTA/SN MDD subgroup for AOEs
included in our secondary a priori hypotheses (10 MDD and 10
controls). In addition to elevated FA in the VTA/SN (Figure 4B), MDD
subjects in the abnormal VTA/SN subgroup exhibited significantly
reduced FA in white matter adjacent to right premotor cortex
(PMCwm). The color bar indicates the range of p values in this figure,
from the threshold (p,0.05) to the order of magnitude of the voxel of
peak significance (i.e. smallest p value) in PMCwm; color in images is
viewed using trilinear interpolation. Cool tones (blues) indicate regions
in which MDD subjects exhibited reduced FA relative to control
subjects. RH: right hemisphere; LH: left hemisphere.
doi:10.1371/journal.pone.0013945.g005
Figure 6. FA difference in the normal VTA/SN MDD subgroup
in secondary a priori areas of evaluation. This figure shows the FA
difference in MDD subjects versus matched healthy controls for the
voxel-based contrast in the normal VTA/SN MDD subgroup for AOEs
included in our secondary a priori hypotheses (12 MMD and 12
controls). In addition to the trend toward reduced FA in the MFB
(Figure 4C), MDD subjects in the normal VTA/SN subgroup also
exhibited a trend toward reduced FA in white matter adjacent to the
right anterior cingulate (ACCwm). Translucent green in image on left
indicates the a priori AOE for ACCwm in the slices shown, which were
used to constrain the initial contrast analysis. The color bar indicates the
range of p values in this figure, from the threshold (p,0.05) to the
order of magnitude of the voxel of peak significance (i.e. smallest p
value) in ACCwm; color in images is viewed using trilinear interpolation.
Cool tones (blues) indicate regions in which MDD subjects exhibited
reduced FA relative to control subjects. RH: right hemisphere; LH: left
hemisphere.
doi:10.1371/journal.pone.0013945.g006
Figure 7. STAI-T (trait anxiety) scores differed between
abnormal and normal VTA/SN MDD subgroups. This figure
shows the STAI-T scores for MDD subgroups and for control subjects
(n=10 abnormal VTA/SN MDD; n=11 normal VTA/SN MDD; n=19
controls). These scores exhibited a similar distribution to VTA/SN FA
values (Figure 4A) across MDD subgroups and controls: Scores for MDD
subjects in the abnormal VTA/SN subgroup (left column of blue data
points) did not overlap with control subject scores (pink data points),
whereas the range of scores for subjects in the normal VTA/SN
subgroup (right column of blue data points) overlapped with control
scores; scores showed a statistically significant difference between MDD
subgroups. The control subject score range also extended below the
range for MDD subjects in the normal VTA/SN subgroup, as it did for
control VTA/SN FA values.
doi:10.1371/journal.pone.0013945.g007
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reproducibility of our findings. Such studies can be conducted
using, not only DTI, but also complementary techniques such as
post-mortem histological evaluation, which require directed
hypotheses such as those generated here.
Registration Methods. Because our hypotheses focused on
specific components of subcortical reward circuitry, we used
registration methods which would maximize precise registration of
these regions. It is therefore important to emphasize that alternative
registration methods might have more accurately or reliably
detected abnormalities in cortical white matter regions in MDD
subjects. We did, however, focus some of our manual registration
points on ventraland medial prefrontal cortical regions to maximize
the likelihood that the SGC, FOC, and ACC regions included in
our secondary a priori hypotheses would be well registered.
Spatial resolution of our a priori regions. Small
subcortical nuclei and small white matter fiber tracts inherently
have lower effective spatial resolution than cortical regions, and
this is a limitation particularly when using the spatial resolution of
standard DTI sequences (2 mm). In the current study we aimed to
optimize the signal at this spatial resolution by using directed
registration methods to maximize alignment in our a priori regions.
We also note in our Methods that previous studies have
successfully detected abnormalities in the VTA/SN region when
gross pathology was present [65,66], suggesting that detection of
biological abnormalities in this region should be feasible.
Potential confounds of cardiorespiratory movement.
Because the brainstem is particularly susceptible to motion artifact
from arterial or respiratory pulsation [92], it cannot be ruled out that
such movements influenced our data. However, in the case of DTI,
image acquisition is integrated over a significant period of time (,10
minutes), and is therefore less susceptible than functional MRI (fMRI)
to the effects of such artifacts leading to individual differences. Unless
patients exhibited different cardiorespiratory features than controls (or
patients differed across subgroups), differences in cardiorespiratory
function would be expected to average out, or in the worst case lead to
increased variance of the signal in one cohort, reducing the likelihood
of a statistically significant finding. Furthermore, all subjects in this
study were thoroughly assessed by review of systems and physical exam
by a physician, from which no such physical differences were discerned
across groups or subgroups.
Are microstructural abnormalities primary or secondary
to MDD?. We cannot be certain whether the observed
microstructural abnormalities in our MDD subjects were the
cause or the result (or both) of the illness or its symptoms. Future
studies in larger cohorts and with repeated measures will be
necessary to further assess the primacy of abnormalities observed in
our study. Such studies will also be needed to evaluate the effects of
other factors secondary to MDD, such as tobacco use. Since only
three of the 22 MDD subjects in this cohort were current or
previous smokers, it is unlikely that our results reflect FA
abnormalities secondary to tobacco use. Specifically, this supports
the idea that the VTA/SN abnormality could be observed in the
absence of tobacco use. Conversely, the controlsubject who smoked
(and haddone sofor37 years)exhibitedthesecond lowestVTA/SN
FA value (0.24) in the control cohort, indicating that smoking is not
sufficient to produce the VTA/SN FA abnormality.
Medication status of MDD subjects and DTI
findings. Because animal literature in depression [93,94] and
more recently human literature in movement disorders [95] suggests
that treatment of symptoms of a disorder may influence brain
microstructure, it is important to consider whether some of the
observations in our study might have been brought about by
medication.
Three factors argue that our main findings were not affected by
medication status, although future studies will be required to
prospectively evaluate whether antidepressants affect brain
microstructure as detected by DTI. First, because our patient
population was drawn partially from recently diagnosed (i.e.
untreated) patients or patients who did not respond to antidepres-
sant medications in the past; the cohort here included a number of
patients who had either never taken or were not currently taking
antidepressants (Table 1). Second, similar proportions of patients
in the normal and abnormal VTA/SN subgroups were on
medications (3/10 in the abnormal VTA/SN subgroup; 4/12 in
the normal VTA/SN subgroup) at the time of scanning. Third,
individual data points indicate there were subjects in each of the
two MDD subgroups who had never taken antidepressants so it is
unlikely that the MDD DTI subgrouping, which was based on
individual rather than group measures, was an effect of medication
or medication differences between subgroups.
Conclusion
In this study, MDD subjects exhibited brain microstructural
abnormalities in the ventral tegmentum, a primary component of
the subcortical reward/aversion circuitry. These abnormalities
subdivided the cohort into two subgroups which exhibited similar
core depressive symptoms, but differences in trait anxiety. These
findings add direct support to the hypothesis that alterations
in brain reward/aversion circuitry play a role in the etiology of
MDD [1].
Supporting Information
Text S1 Registration and AOE segmentation methods. De-
scribes the anatomical landmarks used in the manual registration
step for FA maps, and the procedures used to segment our a priori
areas of evaluation (AOEs).
Found at: doi:10.1371/journal.pone.0013945.s001 (0.05 MB
DOC)
Table 5. MDD Symptom Measures in Abnormal Versus Normal VTA/SN MDD Subgroups.
Symptom
Mean
Abnormal VTA/SN subgroup
Mean
Normal VTA/SN subgroup tt e s tstatistics
Depression severity (IDS-SR) 38.00610.58 3468.68 t(2,16)=1.24, p=0.23
Anhedonia 1.3860.52 1.2560.97 t(2,18)=0.38, p=0.71
Sadness 2.4460.53 1.8361.03 t(2,19)=1.77, p=0.095
Psychomotor symptoms 1.2560.89 1.0061.04 t(2,18)=0.58, p=0.57
Trait anxiety 61.8067.32 51.2768.96 t(2,19)=2.96, p = 0.0084
doi:10.1371/journal.pone.0013945.t005
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(A) coronal and (B) axial slices through average FA maps for
control subjects (left column) and MDD subjects (right column)
show that registration accuracy of images used in group contrasts
was similar between groups and, to illustrate the visibility of
anatomy on these images. Coronal images are at y=-18.3 and
axial images at z=3.5 in MNI Talairach coordinates. RH: right
hemisphere; LH: left hemisphere.
Found at: doi:10.1371/journal.pone.0013945.s002 (0.91 MB
TIF)
Figure S2 Ventral tegmentum area of evaluation (AOE). This
figure shows the primary a priori AOE in the VTA/SN. A priori
AOEs were segmented on the average control FA map and then
used to constrain the voxels considered in the initial contrast
analysis for MDD versus control cohorts. The image on the left in
(A) illustrates the visibility of regions and landmarks used for
segmentation of the VTA/SN and the three images to the right
depict the AOE in translucent green from (left to right) an axial
view (the primary orientation in which segmentation was done), a
coronal view, and a sagittal view. In (B) the AOE is superimposed
on the average MDD FA map at the same locations. RH: right
hemisphere; LH: left hemisphere.
Found at: doi:10.1371/journal.pone.0013945.s003 (0.52 MB
TIF)
Figure S3 Medial forebrain bundle area of evaluation (AOE).
This figure shows the primary a priori AOE in the medial
forebrain bundle (MFB), which also coincided with and included
the lateral nucleus of the hypothalamus (LNH). A priori AOEs
were segmented on the average control FA map and then used to
constrain the voxels considered in the initial contrast analysis for
MDD versus control cohorts. The image on the left in (A)
illustrates the visibility of regions and landmarks used for
segmentation of the MFB/LNH and the three images to the right
depict the AOE in translucent green from (left to right) a coronal
view (the primary orientation in which segmentation was done), an
axial view, and a sagittal view. In (B) the AOE is superimposed on
the average MDD FA map at the same locations. RH: right
hemisphere; LH: left hemisphere.
Found at: doi:10.1371/journal.pone.0013945.s004 (0.65 MB
TIF)
Figure S4 Amygdalofugal pathway area of evaluation (AOE).
This figure shows the primary a priori AOE in the amygdalofugal
pathway, which also coincided with and included the substantia
inominota. A priori AOEs were segmented on the average control
FA map and then used to constrain the voxels considered in the
initial contrast analysis for MDD versus control cohorts. The
image on the left in (A) illustrates the visibility of regions and
landmarks used for segmentation of the amygdalofugal pathway/
substantia inominota and the three images to the right depict the
AOE in translucent green from (left to right) a coronal view (the
primary orientation in which segmentation was done), an axial
view, and a sagittal view. In (B) the AOE is superimposed on the
average MDD FA map at the same locations. RH: right
hemisphere; LH: left hemisphere.
Found at: doi:10.1371/journal.pone.0013945.s005 (0.70 MB
TIF)
Figure S5 Ventral tegmentum group difference cluster. This
figure shows the cluster detected within the VTA/SN a priori
AOE in the voxel-based contrast analysis of MDD versus control
cohorts. This cluster was used to extract values from individual FA
maps for use in the follow-up analyses (main text) and permutation
test (Dataset SI). (A) Images illustrating the average control FA
map (left image), and a priori AOE segmented on that map (right
image) that was used to constrain the voxel-based analysis. (B) The
cluster of voxels (at right, shown on average control and MDD FA
maps, respectively) that met the uncorrected p,0.05 cluster
threshold on the p map of the initial MDD versus control voxel-
based contrast analysis (left image) and fell within the VTA/SN
AOE. Clusters were identified on p maps that had not been
smoothed, and thus, p maps are illustrated here without smoothing
or interpolation. RH: right hemisphere; LH: left hemisphere.
Found at: doi:10.1371/journal.pone.0013945.s006 (0.46 MB
TIF)
Figure S6 Medial forebrain bundle group difference cluster.
This figure shows the cluster detected within the MFB/LNH a
priori AOE in the voxel-based contrast analysis of MDD versus
control cohorts. This cluster was used to extract values from
individual FA maps for use in the follow-up analyses (main text) and
permutation test (Dataset SI). (A) Images illustrating the average
control FA map (left image), and a priori AOE segmented on that
map (right image) that was used to constrain the voxel-based
analysis. (B)The cluster of voxels (at right, shown onaverage control
and MDD FA maps, respectively) that met the uncorrected p,0.05
cluster threshold on the p map of the initial MDD versus control
voxel-based contrast analysis (left image) and fell within the MFB/
LNH AOE. Clusters were identified on p maps that had not been
smoothed, and thus, p maps are illustrated here without smoothing
or interpolation. RH: right hemisphere; LH: left hemisphere.
Found at: doi:10.1371/journal.pone.0013945.s007 (0.51 MB
TIF)
Figure S7 Examples of secondary a priori areas of evaluation
(AOEs). This figure shows slices through each of the five
segmentations included in our secondary a priori AOEs, including
white matter adjacent to (A) dorsolateral prefrontal cortex
(DLPFCwm), (B) anterior cingulate cortex (ACCwm), (C) para-
cingulate cortex (PACwm), (D) orbitofrontal cortex (FOCwm), and
(E) subgenual prefrontal cortex (SGCwm).
Found at: doi:10.1371/journal.pone.0013945.s008 (0.74 MB TIF)
Dataset S1 Permutation tests. Reports the methods and results
of the permutation analysis conducted as a complement to the
voxel-wise contrasts of FA maps.
Found at: doi:10.1371/journal.pone.0013945.s009 (0.12 MB
DOC)
Dataset S2 VT abnormalities and laterality. Analysis evaluating
whether right hemisphere VT abnormalities in the MDD cohort
reflected a loss of normal hemispheric asymmetry in this region or
a bilateral change that was simply more significant in one
hemisphere than the other.
Found at: doi:10.1371/journal.pone.0013945.s010 (0.03 MB
DOC)
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